Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Key Inclusion Criteria: * Participants were male or female aged between 2 and 18 years (inclusive). * Participants had a documented history of Dravet Syndrome that was not completely controlled by current antiepileptic drugs. * Participants took one or more antiepileptic drugs at a dose that had been stable for at least four weeks. * All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation) were stable for four weeks prior to screening and participants were willing to maintain a stable regimen throughout the study. Key Exclusion Criteria: * Participants had clinically significant unstable medical conditions other than epilepsy. * Participants had clinically relevant symptoms or a clinically significant illness in the four weeks prior to screening or randomization, other than epilepsy. * Participants were currently using or had in the past used recreational or medicinal cannabis or synthetic cannabinoid based medications (including Sativex®) within the three months prior to study entry and were unwilling to abstain for the duration for the study. * Participants had any known or suspected hypersensitivity to cannabinoids or any of the excipients of the investigational medicinal products. * Participants had been part of a previous clinical trial involving another investigational product in the previous six months. * There were plans for the participants to travel outside their country of residence during the study. * Participants pre…